Group One Trading
SYRE icon

Group One Trading’s Spyre Therapeutics SYRE Stock Holding History

Group One Trading’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121K Buy
2,400
+1,900
+380% +$71.6K ﹤0.01% 4563
2025
Q4 		$16.4K Buy
+500
New +$13.1K ﹤0.01% 6502
2025
Q2 		– Sell
-33,200
Closed -$536K – 8635
2025
Q1 		$536K Buy
+33,200
New +$691K ﹤0.01% 3019
2023
Q3 		– Sell
-12
Closed -$135 – 8285
2023
Q2 		$135 Sell
12
-8
-40% -$38 ﹤0.01% 7494
2023
Q1 		$145 Hold
20
– – ﹤0.01% 7016
2022
Q4 		$225 Buy
+20
New +$359 ﹤0.01% 7027
2021
Q3 		– Sell
-600
Closed -$104K – 8772
2021
Q2 		$104K Hold
600
– – ﹤0.01% 5913
2021
Q1 		$119K Buy
+600
New +$115K ﹤0.01% 5502
2019
Q4 		– Sell
-4
Closed -$1K – 5600
2019
Q3 		$1K Hold
4
– – ﹤0.01% 5010
2019
Q2 		$1K Buy
+4
New +$691 ﹤0.01% 4835

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Group One Trading's SYRE Position: Q1 2026 in Review

Group One Trading increased its Spyre Therapeutics (SYRE) stake by 125% in Q1 2026, buying an estimated $18.9K and bringing the position to 901 shares worth $45.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5329.

Group One Trading first reported a position in SYRE in Q3 2020 and has held it in 13 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Group One Trading held 901 shares of Spyre Therapeutics worth $45.4K as of Q1 2026.
  • Group One Trading bought 501 Spyre Therapeutics shares in Q1 2026, an estimated $18.9K.
  • Spyre Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #5329 holding.
  • Group One Trading first reported a position in Spyre Therapeutics in Q3 2020 and has held it in 13 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.